PI3K inhibitors are a class of small molecule drugs that target the PI3K enzyme, aiming to directly inhibit the abnormal activation of the PI3K/AKT signaling pathway caused by mutations in the PIK3CA gene, thereby inhibiting tumor growth and metastasis. The gene discussed is AKT1; the disease is neoplasm.